Ascent Group LLC Acquires Shares of 3,199 Edwards Lifesciences Corporation $EW

Ascent Group LLC acquired a new stake in shares of Edwards Lifesciences Corporation (NYSE:EW) during the 2nd quarter, HoldingsChannel reports. The fund acquired 3,199 shares of the medical research company’s stock, valued at approximately $250,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Quantbot Technologies LP purchased a new position in Edwards Lifesciences during the first quarter valued at $26,000. SouthState Corp purchased a new position in Edwards Lifesciences during the first quarter valued at $27,000. Rossby Financial LCC purchased a new position in Edwards Lifesciences during the first quarter valued at $29,000. Costello Asset Management INC acquired a new stake in shares of Edwards Lifesciences in the first quarter valued at about $29,000. Finally, Global X Japan Co. Ltd. raised its position in shares of Edwards Lifesciences by 116.1% in the first quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company’s stock valued at $29,000 after buying an additional 216 shares during the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. The Goldman Sachs Group reiterated a “buy” rating on shares of Edwards Lifesciences in a research report on Friday, July 25th. Mizuho increased their target price on shares of Edwards Lifesciences from $87.00 to $95.00 and gave the company an “outperform” rating in a research report on Friday, July 25th. Morgan Stanley increased their target price on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the company an “equal weight” rating in a research report on Tuesday, July 15th. Truist Financial increased their target price on shares of Edwards Lifesciences from $81.00 to $82.00 and gave the company a “hold” rating in a research report on Friday, July 25th. Finally, William Blair upgraded shares of Edwards Lifesciences to a “strong-buy” rating in a research report on Friday, July 25th. Three research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $87.06.

Insider Buying and Selling

In other news, VP Daniel J. Lippis sold 4,114 shares of the business’s stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $79.46, for a total transaction of $326,898.44. Following the completion of the sale, the vice president owned 22,002 shares in the company, valued at approximately $1,748,278.92. The trade was a 15.75% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Larry L. Wood sold 8,950 shares of the business’s stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $78.06, for a total transaction of $698,637.00. Following the sale, the insider owned 206,900 shares of the company’s stock, valued at $16,150,614. This represents a 4.15% decrease in their position. The disclosure for this sale can be found here. 1.29% of the stock is owned by insiders.

Edwards Lifesciences Trading Down 1.3%

NYSE EW opened at $75.75 on Thursday. The firm has a 50 day simple moving average of $78.28 and a 200-day simple moving average of $76.05. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. Edwards Lifesciences Corporation has a one year low of $64.89 and a one year high of $83.00. The firm has a market cap of $44.47 billion, a price-to-earnings ratio of 10.90, a PEG ratio of 3.69 and a beta of 1.05.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The company had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.49 billion. During the same quarter in the previous year, the firm earned $0.70 earnings per share. The firm’s quarterly revenue was up 11.9% on a year-over-year basis. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Equities research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.